JCO Global Oncology (Mar 2024)

Increasing Annual Cancer Incidence in Patients Age 20-49 Years: A Real-Data Study

  • Nuria Ribelles,
  • Javier Pascual,
  • Laura Galvez-Carvajal,
  • Sofía Ruiz-Medina,
  • Javier Garcia-Corbacho,
  • Jose Carlos Benitez,
  • Maria Emilia Dominguez-Recio,
  • Esperanza Torres,
  • Lucia Oliva,
  • Manuel Zalabardo,
  • Antonio Rueda,
  • Emilio Alba

DOI
https://doi.org/10.1200/GO.23.00363
Journal volume & issue
no. 10

Abstract

Read online

PURPOSEData from population-based studies have shown an increased incidence of certain types of neoplasms in patients younger than 50 years (early-onset cancer [EOC]); however, little information is derived from other real-world data sources. In a nonpopulation registry, we analyzed changes in the incidence of several neoplasms in successive generations.METHODSThis cross-sectional study included all patients with a cancer diagnosis registered in one university hospital in Málaga, Spain, between 1998 and 2021, and 18 neoplasms were analyzed. For each neoplasm, the proportion of patients younger than 50 years and age 50 years and older (late-onset cancer [LOC]) of the total number of patients diagnosed each year was determined. In addition, the age limit was lowered to 45-40 years. Changes in these proportions between each year and the following year were assessed by calculating the annual percentage change (APC), and a final assessment of these changes was performed by determining the average APC (AAPC).RESULTSOf the 24,596 patients, 5,466 (22.2%) had EOC, and 19,130 (77.8%) had LOC. The incidence of all tumors increased throughout the study period in both age groups. The AAPC increase was higher in patients with EOC than in those with LOC for the following neoplasms: head and neck (6.1% v 4.6%), colon (11.0% v 8.2%), testicular (16.3% v –13.1%), non-Hodgkin lymphoma (8.4% v 5.9%), rectum (16.1% v 6.8%), kidney (27.8% v 20.1%), and sarcoma (43.4% v 28.6%). This increase was confirmed in patients younger than 45 years and 40 years.CONCLUSIONOur results are consistent with the data published for most tumor sites analyzed. This global public health problem requires the utmost attention to decrease excess cancer in young patients.